Alzheimer's Disease Histone Methylation and Epigenetic Writer Companies

Overview

flowchart TD
    companies_ad_histone_methylati["Alzheimers Disease Histone Methylation and Epig"]
    style companies_ad_histone_methylati fill:#4fc3f7,stroke:#333,color:#000
    companies_ad_histone_0["Key Therapeutic Approaches"]
    companies_ad_histone_methylati -->|"includes"| companies_ad_histone_0
    style companies_ad_histone_0 fill:#81c784,stroke:#333,color:#000
    companies_ad_histone_1["EZH2 and H3K27 Methylation Inhibitors"]
    companies_ad_histone_methylati -->|"includes"| companies_ad_histone_1
    style companies_ad_histone_1 fill:#ef5350,stroke:#333,color:#000
    companies_ad_histone_2["Epizyme Inc."]
    companies_ad_histone_methylati -->|"includes"| companies_ad_histone_2
    style companies_ad_histone_2 fill:#ffd54f,stroke:#333,color:#000
    companies_ad_histone_3["Constellation Pharmaceuticals Ultragenyx"]
    companies_ad_histone_methylati -->|"includes"| companies_ad_histone_3
    style companies_ad_histone_3 fill:#ce93d8,stroke:#333,color:#000
    companies_ad_histone_4["C4 Therapeutics"]
    companies_ad_histone_methylati -->|"includes"| companies_ad_histone_4
    style companies_ad_histone_4 fill:#4fc3f7,stroke:#333,color:#000
    companies_ad_histone_5["DOT1L and H3K79 Methylation Inhibitors"]
    companies_ad_histone_methylati -->|"includes"| companies_ad_histone_5
    style companies_ad_histone_5 fill:#81c784,stroke:#333,color:#000

This category page consolidates biotechnology and pharmaceutical companies developing histone methyltransferase (HMT) modulators, histone demethylase (HDM/LSD) inhibitors, and broader epigenetic writer/eraser mechanisms for Alzheimer’s disease. These approaches target the “writers” (enzymes that add methyl marks) and “erasers” (enzymes that remove methyl marks) of epigenetic regulation — a key driver of gene expression dysregulation in neurodegeneration.

This page is distinct from (but related to) the Alzheimer’s Disease HDAC and Epigenetic Inhibitor Companies page, which covers HDAC inhibitors (deacetylase inhibitors), BET bromodomain inhibitors, and reader domain inhibitors. While HDACs remove acetyl marks, HMTs and HDMs regulate methylation marks — a complementary epigenetic mechanism.

Key Therapeutic Approaches

EZH2 and H3K27 Methylation Inhibitors

Epizyme Inc.

• Focus: EZH2 inhibitor development for oncology and CNS applications

• Lead Candidate: Tazemetostat (Tazverik/Ezorkspace)

• Mechanism: EZH2 is the catalytic subunit of PRC2 that tri-methylates H3K27 (H3K27me3). In AD, aberrant H3K27me3 accumulation represses synaptic plasticity genes. EZH2 inhibition restores expression of memory-related genes.

• Indication: Alzheimer’s disease (exploratory), oncology

• Stage: Approved for epithelioid sarcoma and follicular lymphoma; AD preclinical

• Notes: Originally oncology-focused but exploring neurodegenerative applications. Partnered with Roche on combination approaches.

Epizyme — Note: Company page does not exist yet — this is a reference placeholder

Constellation Pharmaceuticals (Ultragenyx)

• Focus: EZH2 and DOT1L dual inhibitors

• Lead Candidates: CPI-0209 (EZH2 inhibitor), CPI-1809 (dual EZH2/DOT1L)

• Mechanism: Combined EZH2 (H3K27) and DOT1L (H3K79) inhibition for enhanced epigenetic modulation

• Indication: Alzheimer’s disease, oncology

• Stage: Preclinical

• Notes: Constellation was acquired by Ultragenyx in 2023. Pipeline includes CNS applications for epigenetic modulators.

C4 Therapeutics

• Focus: Molecular glue degraders targeting epigenetic writers

• Lead Candidate: CFT-8634 (RET degrader) — not directly EZH2 but related platform

• Mechanism: Using Molecular glue technology to degrade EZH2 and other epigenetic targets

• Indication: Alzheimer’s disease (exploratory), oncology

• Stage: Discovery

• Notes: DegrambulX platform targets epigenetic writers for degradation rather than inhibition

DOT1L and H3K79 Methylation Inhibitors

Imago Biosciences

• Focus: DOT1L inhibitor development

• Lead Candidate: IMG-7289 (BME-109)

• Mechanism: DOT1L methylates H3K79 (H3K79me2), which is involved in transcription elongation and DNA damage response. In AD, DOT1L activity is dysregulated, affecting neuronal survival pathways.

• Indication: Alzheimer’s disease, myelofibrosis

• Stage: Preclinical (CNS), Phase 1/2 (oncology)

• Notes: Acquired by Merck (MSD) in 2022 for $1.35B. Exploring CNS applications for DOT1L inhibition.

LSD1/KDM1A and Histone Demethylase Inhibitors

Oryzon Genomics SA

• Focus: LSD1/KDM1A and MAO-B dual inhibitors

• Lead Candidate: Iadademstat (ORY-2001)

• Mechanism: LSD1 (KDM1A) demethylates H3K4me1/2 and H3K9me1/2 — key marks for gene activation and repression. In AD, LSD1 overactivity contributes to synaptic gene silencing. Dual LSD1/MAO-B inhibition provides neuroprotection.

• Indication: Alzheimer’s disease, Parkinson’s disease

• Stage: Phase 2 (LIGHT trial for AD)

• Notes: Spanish biotech (Madrid) with proprietary epigenetics platform. ORY-2001 has shown cognitive improvement in AD models.

GSK (GlaxoSmithKline)

• Focus: LSD1/KDM1A inhibitor development

• Lead Candidates: GSK2879552, GSK-LSD1

• Mechanism: Selective LSD1 inhibition for epigenetic correction in neurodegenerative disease

• Indication: Alzheimer’s disease, oncology

• Stage: Preclinical/Phase 1

• Notes: Multiple LSD1 programs in development. Partnered with various academic groups for CNS applications.

Cytozin Inc.

• Focus: KDM1A/LSD1 inhibitors for neuroinflammation

• Lead Program: CYT-387 (novel LSD1 modulator)

• Mechanism: Modulate inflammatory gene expression through LSD1 inhibition

• Indication: Alzheimer’s disease

• Stage: Discovery

• Notes: Emerging biotech focused on epigenetic immunomodulation

PRMT5 and Arginine Methylation Inhibitors

Accent Therapeutics

• Focus: PRMT5 and type I/II arginine methyltransferase inhibitors

• Lead Candidate: ATX-002 (PRMT5 inhibitor)

• Mechanism: PRMT5 mediates symmetric dimethylation of arginine (H3R2me2s, H4R3me2s), critical for splicing and transcription. PRMT5 is elevated in AD brains and contributes to tau pathology.

• Indication: Alzheimer’s disease, oncology

• Stage: Discovery/Preclinical

• Notes: Founded by scientists from MIT and Dana-Farber. Raised $40M Series B in 2021.

GSK (GlaxoSmithKline)

• Focus: PRMT5 inhibitor programs

• Lead Candidate: GSK-3206308 (PF-06839234)

• Mechanism: PRMT5 inhibition for modulating splicing and transcription dysregulation in AD

• Indication: Alzheimer’s disease, oncology

• Stage: Discovery/Preclinical

• Notes: Multiple PRMT5 programs across therapeutic areas

JMJD3/KDM6B and H3K27 Demethylase Inhibitors

Roche

• Focus: JMJD3/KDM6B inhibitor development

• Mechanism: JMJD3 (KDM6B) demethylates H3K27me3 to activate gene expression. While demethylases are typically activating, JMJD3 overactivity in AD can paradoxically repress neuroprotective genes.

• Indication: Alzheimer’s disease

• Stage: Discovery

• Notes: Academic partnerships for KDM6B targeting in neurodegeneration

BMS (Bristol Myers Squibb)

• Focus: KDM6B/JMJD3 inhibitor programs

• Mechanism: Modulate H3K27me3 dynamics to restore synaptic gene expression

• Indication: Alzheimer’s disease

• Stage: Discovery

• Notes: Part of broader epigenetic drug discovery efforts

Pipeline Overview

Mechanism of Action

Epigenetic Writers and Erasers in Alzheimer’s Disease

Histone Methylation Overview:

EZH2 Inhibition in AD

EZH2 is the catalytic subunit of Polycomb Repressive Complex 2 (PRC2), which tri-methylates H3K27. In AD:

• H3K27me3 accumulation represses synaptic plasticity genes (BDNF, Arc, c-Fos)

• EZH2 inhibitors restore expression of memory-related genes

• Benefits: Improved synaptic plasticity, cognitive function in preclinical models

• Challenge: EZH2 has both protective and pathogenic roles — timing matters

DOT1L Inhibition in AD

DOT1L methylates H3K79, regulating transcription elongation and DNA damage response:

• H3K79me2 dysregulation affects neuronal survival pathways

• DOT1L inhibitors may restore proper transcription programs

• Clinical potential: Early-stage, primarily oncology-focused

LSD1/KDM1A Inhibition in AD

LSD1 (also known as KDM1A) is a flavin-dependent histone demethylase:

• Targets: H3K4me2 (activation mark), H3K9me2 (repression mark)

• In AD: LSD1 overactivity silences synaptic and mitochondrial genes

• Benefits: Restores synaptic gene expression, reduces neuroinflammation

• Dual-action: Some LSD1 inhibitors also inhibit MAO-B for additional neuroprotection

PRMT5 Inhibition in AD

PRMT5 is a type II arginine methyltransferase:

• Symmetric dimethylation of arginine residues on histones

• In AD: PRMT5 elevation contributes to tau pathology and splicing defects

• Benefits: May reduce tau phosphorylation and improve RNA splicing

• Challenge: PRMT5 has essential functions — therapeutic window needed

KDM6B/JMJD3 Inhibition in AD

JMJD3 (KDM6B) demethylates H3K27me3:

• Normally: Activates developmental genes by removing repressive marks

• In AD: Paradoxical overactivity can dysregulate gene programs

• Modulation: Rather than full inhibition, precise modulation needed

Cross-Links

• Alzheimer’s Disease HDAC and Epigenetic Inhibitor Companies

• Alzheimer’s Disease Epigenetic and Metabolic Therapy Companies

• Epigenetics in AD

• Tau Pathology and Therapeutics

• Synaptic Plasticity Mechanisms

• Neuroinflammation Pathway